EX-99.1
2
a5321074ex991.txt
EXHIBIT 99.1

                                                                    Exhibit 99.1



                        Theragenics(R) Reports Revenue &
                 Earnings for Fourth Quarter and Year-End 2006

          Company Reports Best Revenue Year and Quarter Ever,
  and Fourth Consecutive Quarter of Profitability Post Restructuring



    BUFORD, Ga.--(BUSINESS WIRE)--Jan. 30, 2007--Theragenics
Corporation(R) (NYSE: TGX), a medical device company serving the
cancer treatment and surgical products markets, today announced
consolidated financial results for the fourth quarter and year ended
December 31, 2006. Consolidated revenue for the quarter was $14.8
million, an increase of $3.4 million, or 30% over the fourth quarter
of 2005. For the 12-month period, consolidated revenue was $54.1
million, an increase of $9.8 million, or 22%, compared to the prior
year. Net income for the quarter was $3.7 million or $0.11 per share,
compared to a net loss of $(236,000), or $(0.01) per share in the
fourth quarter of 2005. For the year, net income was $6.6 million, or
$0.20 per share, compared to a net loss of $(29.0) million, or $(0.93)
per share, in the comparable 2005 period. Net income for the 2006
periods include the release of a deferred tax asset valuation
allowance, resulting in an increase to net income of $1.8 million, or
$0.06 per share in the fourth quarter and $3.3 million, or $0.10 per
share, for the full year. The 2005 and 2006 periods also include
pre-tax restructuring charges of $33.4 million and $369,000
respectively. The Company's results include the results of operations
of its subsidiaries subsequent to the dates of each respective
acquisition. Theragenics acquired CP Medical Corp. on May 6, 2005 and
Galt Medical Corp. on August 2, 2006.

    "In many ways we have just completed our best year," stated M.
Christine Jacobs, Chief Executive Officer and President. "2006 was our
highest annual revenue ever, and the fourth quarter was our highest
quarterly revenue ever. CP Medical and Galt, which make up our
surgical products business, contributed 46% of our revenue in the
fourth quarter. As recently as the first quarter of 2005, 100% of our
revenue came from our brachytherapy business. We are accomplishing our
diversification goals as we are now more diversified than at any time
in our twenty-five year history."

    Ms. Jacobs continued, "Our efforts to work with Congress in
protecting access to brachytherapy were recognized in December 2006
when the Tax Reform and Health Care Act of 2006 became law. This law
provides important safeguards to protect the immediate and long-term
reimbursement for seeds. Adding to these accomplishments, we delivered
four consecutive profitable quarters in 2006, something we haven't
done since 2002. We are thrilled with our results this year, and
intend to continue building on our momentum. We are committed to
investing for growth at CP Medical and Galt, maintaining our
leadership in brachytherapy, and continuing to search for acquisition
candidates that can leverage our surgical products businesses. Our
balance sheet remains strong and capable of supporting our strategy."

    A comparison of non-GAAP revenue and operating income by segment,
excluding non-recurring items, is summarized in Table III to this
press release. Table IV includes a reconciliation of GAAP net earnings
to earnings before interest, taxes, depreciation and amortization
(EBITDA).

    Theragenics will host a conference call today at 11:00 a.m.
Eastern Time. To access the call, dial 800-538-9844 or 706-634-7274
and provide the conference ID code 6306801. This call is also being
broadcast live over the Internet, and a recording will be available
for one month on the Company's website. To access the webcast, log on
to www.theragenics.com and select Investor Relations followed by
selecting company presentations. You also can access a phone replay of
the call until Midnight, February 6, 2007, by dialing 800-642-1687 or
706-645-9291 and providing the conference ID code: 6306801.

    Theragenics Corporation(R)(NYSE: TGX) operates two business
segments: its brachytherapy seed business and its surgical products
business. The brachytherapy business manufactures and markets its
premiere product, the palladium-103 TheraSeed(R) device and I-Seed, an
iodine-125 based device, which are used primarily in the minimally
invasive treatment of localized prostate cancer. Its surgical products
business manufactures and distributes wound closure, needles, and
other surgical products used in the urology, veterinary, orthopedic
and other markets, and disposable medical devices used for vascular
access. For additional information, call Theragenics' Investor
Relations Department at (800) 998-8479 or visit www.theragenics.com.

    This press release contains non-GAAP financial measures used by
Management in its analysis of the Company's operating performance.
Management believes presentation of financial measures excluding the
impact of certain identified items provides supplemental information
that is helpful to an understanding of the operating results of the
Company's businesses and period-to-period comparisons of performance.
Non-GAAP financial measures should be considered in addition to, but
not as a substitute for, the Company's reported GAAP results.

    This release contains forward looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, the
accuracy of which is necessarily subject to risks and uncertainties,
including, without limitation, statements regarding the contribution
of Galt Medical Corp. and CP Medical to Theragenics' sales, impact on
net income, future growth, and anticipated positive results in
general. Actual results may differ materially due to a variety of
factors, including, among other things, uncertainties related to the
integration of Galt and CP Medical into the Theragenics organization,
capitalization on opportunities for growth within the Galt and CP
Medical business plans, ability to recognize value from areas of
shared expertise, risks and uncertainties related to competition
within the medical device industry, development and growth of new
applications within the markets for vascular access, wound closure,
brachytherapy and more broadly, medical devices, competition from
other companies within the vascular access, wound closure and medical
device markets, competition from other methods of treatment, new
product development cycles, integration risks, effectiveness and
execution of marketing and sales programs by Theragenics and its
distributors, changes in product pricing by Theragenics or other
brachytherapy seed producers, changes in costs of materials used in
production processes (especially as it relates to isotope production),
continued acceptance of the products by the market, continued demand
for palladium-103, introduction and/or availability of competitive
products by others, potential changes in third-party (including CMS)
reimbursement, physician training, third-party distribution
agreements, ability to execute on acquisition opportunities on
favorable terms and successfully integrate any acquisitions, and other
factors set forth from time to time in the Company's Securities and
Exchange Commission filings.

    All forward looking statements and cautionary statements included
in this document are made as of the date hereby based on information
available to the Company as of the date hereof, and the Company
assumes no obligation to update any forward looking statement or
cautionary statement.



TABLE I
THERAGENICS AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF
 OPERATIONS (Unaudited)
(In thousands except per share data)

                                  Three Months Ended     Year Ended
                                12/31/06   12/31/05 12/31/06 12/31/05
                              ----------------------------------------
Product sales                    $14,630    $11,216  $53,076  $43,693
License fees                         162        141    1,020      577
                              ----------------------------------------
Total revenue                     14,792     11,357   54,096   44,270
Cost of sales                      7,954      5,891   27,752   23,763
                              ----------------------------------------
     Gross profit                  6,838      5,466   26,344   20,507
Operating expenses:
     Selling, general &
      administrative               4,674      5,137   19,951   19,652
     Amortization of purchased
      intangibles                    525        187    1,371      500
     Research & development          181        258      805    3,632
      Restructuring expenses           -        475      369   33,390
      Gain on sale of assets           -          -     (201)       -
                              ----------------------------------------
                                   5,380      6,057   22,295   57,174
                              ----------------------------------------
     Operating income/(loss)       1,458       (591)   4,049  (36,667)
Other income, net                    180        355    1,104    1,267
                              ----------------------------------------
     Income/(Loss) before
income tax                         1,638       (236)   5,153  (35,400)
                              ----------------------------------------
Income tax benefit                (2,052)         -   (1,402)  (6,394)
                              ----------------------------------------
Net earnings/(loss)               $3,690      $(236)  $6,555 $(29,006)
                              ========================================
Net income/(loss) per
common share, Basic                $0.11     $(0.01)   $0.20   $(0.93)
                              ========================================
Net income/(loss) per
common share, Diluted              $0.11     $(0.01)   $0.20   $(0.93)
                              ========================================
Weighted average shares
   Basic                          33,041     32,027   32,452   31,273
  Diluted                         33,125     32,027   32,540   31,273




TABLE II
THERAGENICS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED
 BALANCE SHEETS
(Unaudited)
(In thousands)

Assets                                  Dec. 31, 2006    Dec. 31, 2005
                                    ----------------------------------
     Cash, short-term investments &
      marketable securities                  $32,980          $45,608
     Trade accounts receivable                 7,556            7,622
     Inventories                               7,433            5,042
     Deferred income tax asset                 7,798                -
     Assets held for sale                      3,400            3,433
     Prepaid expenses and other
      current assets                           3,478            2,720
                                    ----------------------------------
               Total current assets           62,645           64,425
     Property, plant & equipment,
      net                                     30,901           32,766
     Goodwill                                 38,824           18,370
     Other intangible assets                  13,762            6,388
     Other long-term assets                      112              115
                                    ----------------------------------
          Total assets                      $146,244         $122,064
                                    ==================================

Liabilities & Shareholders' Equity
     Accounts payable & accrued
      expenses                                $4,381           $4,172
     Contract termination liability            1,513            1,537
     Long term debt                            7,500                -
     Deferred income tax liability,
      long-term                                6,458                -
     Other long-term liabilities                 561              672
                                    ----------------------------------
               Total liabilities              20,413            6,381
     Shareholders' equity                    125,831          115,683
                                    ----------------------------------
               Total liabilities &
                shareholders' equity        $146,244         $122,064
                                    ==================================




TABLE III
THERAGENICS CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON GAAP FINANCIAL MEASURES
REVENUE BY SEGMENT EXCLUDING NON-RECURRING LICENSE FEES (in thousands)

                   Quarter Ended 12/31/06     Quarter Ended 12/31/05
                 -------------------------- --------------------------
                 Consol-  Brachy- Surgical  Consol-  Brachy- Surgical
                  idated  therapy  products  idated  therapy  products
                 -------- ------- --------- -------- ------- ---------
Revenue, U.S.
 GAAP            $14,792  $8,014    $6,778  $11,357  $8,483    $2,874
Less: non-
 recurring
 license fee           -       -         -        -       -         -
                 -------- ------- --------- -------- ------- ---------
Revenue before
 non-recurring
 license fee     $14,792  $8,014    $6,778  $11,357  $8,483    $2,874
                 ======== ======= ========= ======== ======= =========




                   Year Ended 12/31/06         Year Ended 12/31/05
               --------------------------- ---------------------------
               Consol-  Brachy-  Surgical  Consol-  Brachy-  Surgical
                idated  therapy   products  idated  therapy   products
               -------- -------- --------- -------- -------- ---------
Revenue, U.S.
 GAAP          $54,096  $34,880   $19,216  $44,270  $36,372    $7,898
Less: non-
 recurring
 license fee      (400)    (400)        -        -        -         -
               -------- -------- --------- -------- -------- ---------
Revenue before
 non-recurring
 license fee   $53,696  $34,480   $19,216  $44,270  $36,372    $7,898
               ======== ======== ========= ======== ======== =========




TABLE III - CONTINUED
THERAGENICS CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON GAAP FINANCIAL MEASURES
OPERATING INCOME BY SEGMENT EXCLUDING SPECIAL ITEMS (in thousands)

                    Quarter Ended 12/31/06    Quarter Ended 12/31/05
                   ------------------------- -------------------------
                   Consol- Brachy- Surgical  Consol- Brachy- Surgical
                   idated  therapy  products idated  therapy  products
                   ------- ------- --------- ------- ------- ---------
Operating income
 (loss), U.S. GAAP $1,458    $475      $983   $(591)  $(914)     $323
Special items:
Restructuring
 related items, net     -       -         -     475     475         -
Severance costs not
 related to
 restructuring          -       -         -       -       -         -
                   ------- ------- --------- ------- ------- ---------
Operating income
 (loss) excluding
 special items     $1,458    $475      $983   $(116)  $(439)     $323
                   ======= ======= ========= ======= ======= =========




                  Year Ended 12/31/06         Year Ended 12/31/05
               ------------------------- -----------------------------
               Consol- Brachy- Surgical   Consol-   Brachy-  Surgical
               idated  therapy  products  idated    therapy   products
               ------- ------- --------- --------- --------- ---------
Operating
 income (loss),
 U.S. GAAP     $4,049  $2,122    $1,927  $(36,667) $(38,097)   $1,430
Special items:
 Non-recurring
  license fees   (400)   (400)        -         -         -         -
 Restructuring
  related
  items, net      170     170         -    33,390    33,390         -
 Severance
  costs not
  related to
  restructuring     -       -         -       731       731         -
               ------- ------- --------- --------- --------- ---------
Operating
 income (loss)
 excluding
 special items $3,819  $1,892    $1,927   $(2,546)  $(3,976)   $1,430
               ======= ======= ========= ========= ========= =========




TABLE IV
THERAGENICS CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON GAAP FINANCIAL MEASURES
EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION
 (EBITDA), EXCLUDING SPECIAL ITEMS (in thousands)

                                 Quarter Ended         Year Ended
                               ------------------- -------------------
                               12/31/06  12/31/05  12/31/06  12/31/05
                               --------- --------- --------- ---------
Net earnings (loss), U.S. GAAP   $3,690     $(236)   $6,555  $(29,006)
Income tax benefit               (2,052)        -    (1,402)   (6,394)
Other income, net                  (180)     (355)   (1,104)   (1,267)
                               --------- --------- --------- ---------
Operating income (loss)           1,458      (591)    4,049   (36,667)
Depreciation and amortization     1,867     1,331     6,029     6,818
Stock based compensation
 amortization                        60        52       362       215
                               --------- --------- --------- ---------
    EBITDA                        3,385       792    10,440   (29,634)
Special items:
    Non-recurring license fee
     revenue                          -         -      (400)        -
    Restructuring related items       -       475       170    33,390
    Severance costs not related
     to restructuring                           -         -       731
                               --------- --------- --------- ---------
    EBITDA excluding special
     items                       $3,385    $1,267   $10,210    $4,487
                               ========= ========= ========= =========




    CONTACT: Theragenics Corporation(R), Buford
             Company Contact:
             Frank Tarallo, 800-998-8479 or 770-271-0233
             CFO & Treasurer
             or
             Lisa Rassel, 800-998-8479 or 770-271-0233
             Manager of Investor Relations
             www.theragenics.com




The following information was filed by Theragenics Corp (TGX) on Tuesday, January 30, 2007 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Theragenics Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Theragenics Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account